Finch Therapeutics Group, Inc. (FNCHQ) Stock
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Finch Therapeutics Group, Inc. is headquartered in US.
Finch Therapeutics Group, Inc. (FNCHQ) stock trades at $10.20 with a market capitalization of $16.38M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.18, reflecting a net loss over the last twelve months, price-to-book of 1.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.00 and $16.10, and currently trades 36.6% below its 52-week high.
On profitability, Finch Therapeutics Group, Inc. generates a return on equity (ROE) of -86.83% (negative, reflecting a net loss), return on capital employed of -40.49%.
Official website: www.finchtherapeutics.com
Finch Therapeutics Group, Inc. by the numbers, 2019–2024
Between 2019 and 2024 Finch Therapeutics Group, Inc. reported revenue of $10.0M rising to $0, a change of -100.0% across 6 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $-14.0M.
On a trailing twelve-month basis to Jun '24, revenue is $3.0M and net profit $-14.0M.
Borrowings fell from $143.0M to $28.0M, cash on hand is $16.0M.
Return on equity has averaged -117.9% over five years, and was -155.6% in the most recent year.
The share price itself has compounded at -52.5% a year over five years, 15.6% over three, -16.7% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Finch Therapeutics Group, Inc. (FNCHQ) — frequently asked questions
What is Finch Therapeutics Group, Inc. (FNCHQ) stock price today?
Finch Therapeutics Group, Inc. (FNCHQ) is currently trading at $10.20, up 0.49% today.
What is FNCHQ P/E ratio?
Finch Therapeutics Group, Inc.'s P/E ratio is -1.18. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is FNCHQ return on equity (ROE)?
Finch Therapeutics Group, Inc.'s return on equity (ROE) is -86.83%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Finch Therapeutics Group, Inc.'s market cap?
Finch Therapeutics Group, Inc. has a market capitalization of $16.38M.
Does FNCHQ pay a dividend?
Finch Therapeutics Group, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does FNCHQ carry?
Finch Therapeutics Group, Inc. has a debt-to-equity ratio of 3.06. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is FNCHQ's profit margin?
Finch Therapeutics Group, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is FNCHQ in?
Finch Therapeutics Group, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is FNCHQ listed on?
Finch Therapeutics Group, Inc. trades on OTC under the ticker FNCHQ.
What is FNCHQ's 52-week range?
Over the last year Finch Therapeutics Group, Inc. has traded between $2.00 and $16.10.
Related Healthcare Stocks
Popular Stocks
Screens FNCHQ currently matches
On the figures above, Finch Therapeutics Group, Inc. passes the filters for 1 of our ready-made screens, among them Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.